Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy

Dong Ho Shin, Teresa Nguyen, Bulent Ozpolat, Frederick Lang, Marta Alonso, Candelaria Gomez-Manzano, Juan Fueyo

    Research output: Contribution to journalArticlepeer-review

    27 Scopus citations


    Cancer virotherapy is a paradigm-shifting treatment modality based on virus-mediated oncolysis and subsequent antitumor immune responses. Clinical trials of currently available virotherapies showed that robust antitumor immunity characterizes the remarkable and long-term responses observed in a subset of patients. These data suggest that future therapies should incorporate strategies to maximize the immunotherapeutic potential of oncolytic viruses. In this review, we highlight the recent evidence that the antiviral immunity of the patients may limit the immunotherapeutic potential of oncolytic viruses and summarize the most relevant approaches to strategically redirect the immune response away from the viruses and toward tumors to heighten the clinical impact of viro-immunotherapy platforms.

    Original languageEnglish (US)
    Article numbere002086
    JournalJournal for immunotherapy of cancer
    Issue number4
    StatePublished - Apr 1 2021


    • central nervous system neoplasms
    • immunotherapy
    • oncolytic virotherapy
    • oncolytic viruses

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology
    • Molecular Medicine
    • Oncology
    • Pharmacology
    • Cancer Research


    Dive into the research topics of 'Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy'. Together they form a unique fingerprint.

    Cite this